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One-Pot Synthesis of Unsymmetrical Squaramides 
 
Juan V. Alegre-Requena,a Eugenia Marqués-Lópeza and Raquel P. Herrera*a  
The results concerning the first one-pot synthesis of unsymmetrical squaramides are 
reported. This straightforward procedure allows appealing and commonly used squaramide 
derivatives to be obtained with very good results. The methodology developed in this work 
saves energy, eliminates the purification steps for intermediate products, reduces costs and 
leads to better yields compared to those obtained through the traditional “stop-and-go” 
approach. Moreover, we have proved the efficiency of our process with the synthesis of 
three biologically active structures, improving the results of the previously reported stepwise 
syntheses. Interestingly, this simple and cheap method could attract the interest of 
pharmaceutical and chemical companies aiming to produce these active compounds at a 
large scale. 
 
 
 
Introduction 
The development of one-pot syntheses, in which at least two 
sequential transformations are performed in a single reaction 
flask, has gained much attention in the last decade,1 especially 
when these processes can afford chemicals and drug 
derivatives.1c This growing interest is due to the increasing 
importance of sustainable chemistry, which involves saving 
resources and reducing waste. In stepwise syntheses, after each 
chemical transformation the process is stopped to purify and 
isolate the reaction intermediates previous to the subsequent 
reaction pathway. In this context, one-pot approaches could be 
the best option for reducing time, costs, resources and waste 
generation at an industrial scale, since these processes eliminate 
the purification of the intermediates between individual 
reaction steps, which is, in many cases, where more time and 
resources are wasted. Moreover, by reducing the number of 
synthetic steps and removing the intermediates’ purification 
processes, it is possible to reduce the loss of material and, 
consequently, to increase the overall yield of the reaction 
sequence.2 Interestingly, from a biological and pharmaceutical 
point of view, using one-pot reactions is an attractive way to 
synthesise active compounds through the generation of large 
compound libraries, due to their ability to generate families of 
target products easily. 
 New strategies involving squaramides have attracted 
increasing interest due to their promising properties, becoming 
a fundamental motif in research.3 These compounds have 
unique properties that make them appealing for many different 
areas within chemistry, such as organic synthesis and catalysis 
and even medicine. In fact, since the pioneering work reported 
by Rawal and co-workers in 20084 using squaramides as 
excellent hydrogen bond donor catalysts, this area has been 
experiencing an impressive growth in the organocatalysis 
field.3a 
 Although squaramides have been the focus of many 
intensive studies,3 to the best of our knowledge, unsymmetrical 
squaramides have always been synthesised by using multi-step 
syntheses, which require purifying the reaction intermediates or 
changing the reaction media between synthetic steps. 
Therefore, the novel one-pot approach for synthesizing 
squaramides described in this work requires less time and 
resources and is cleaner than previously reported syntheses 
(Scheme 1). 
 
 
Scheme 1. One‐pot reaction of squaramides 
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 This work was intended to develop a more straightforward 
method for synthesizing squaramides that would enable this 
field to progress and evolve more quickly without the 
disadvantages of previous standard approaches. Moreover, we 
performed these syntheses without an excess of reactants, 
which proves these to be atom-economic processes.5 This not 
only saves resources, but generally also leads to obtaining pure 
final products after a simple filtration.  
 In this work, we report our appealing results concerning the 
first one-pot synthesis of a great number of squaramides 
(Scheme 1).6 Furthermore, in order to demonstrate the wide 
application of this protocol, the syntheses of three biologically 
active structures have been successfully accomplished (Figure 
1). 
 
Figure 1. Target molecules synthesised 
 
Results and Discussion 
Focusing on the first step of the one-pot process and in order to 
check the viability of our idea, we performed an initial 
screening of solvents and concentration of the model reaction, 
shown in Table 1. We analysed which solvent presented the 
highest formation of product 3a, which is the first product 
obtained in the equivalent “stop-and-go” syntheses. 
Consequently, 3a is the first expected intermediate formed in 
the current one-pot approach and its formation is the limiting 
step of this reaction. The first amine addition is crucial in this 
method because an incomplete conversion of the initial reagents 
leads to lower yields of final squaramides 5. This decrease in 
the yield occurs because a smaller amount of intermediate 3 is 
available for the second amine addition, and the remaining 
squarate 1 could also react with the second amine. Thus, the 
generated amount of intermediate 3 limits the overall yield of 
the final squaramides in this one-pot procedure (Scheme 1). 
Table 1. Screening of solvents in the model reaction. 
 
Entry Solvent time  
(h) 
yield  
(%)a 
1 CHCl3 24 47 
2 MeOH 24 59 
3 EtOH 24 53 
4 CH3CN 24 46 
5 DMSO 24 n.r.b 
6 DMF 24 n.r.b 
7 1,4-Dioxane 24 n.r.b 
8 Toluene 24 n.r. b 
9c MeOH 24 69 
10c MeOH 85 >95 
a Conversion calculated by 1H-NMR using dimethyl fumarate as the internal 
standard. b No reaction. c Reaction performed with 0.25 mL of MeOH. 
 Among all the studied solvents, we found MeOH as the best 
choice for the synthesis of intermediate 3a (entry 2), whereas 
no reaction was observed with some polar solvents such as 
DMSO, DMF or 1,4-dioxane (entries 5-7). Non-polar solvents 
such as toluene also showed no reaction (entry 8). This was also 
observed by Luk and coworkers, who demonstrated that the 
addition of the second amine in squaramide synthesis was faster 
when hydrogen-bond donors were employed, concluding that 
solvents with a higher hydrogen-donor character led to better 
reactions rates.3e In our work, this conclusion can be also stated 
since the reaction rates observed in the additions of the first 
amines depended on the hydrogen-bond donor acidities7 of the 
solvents and not on their dielectric constants. However, the use 
of pure water as the solvent was not effective since the 
formation of the final squaramides was low due to the high 
insolubility of intermediate 3a in this medium. Moreover, the 
hydrolysis of squarate 1a in water produced different 
byproducts as observed previously in other works.8 Increasing 
the concentration of the reaction had a pronounced positive 
effect on the yield. When using 0.25 mL of MeOH, 3a was 
obtained in 69% yield, compared to the 59% yield obtained 
when 0.5 mL of MeOH was used (entry 9 vs entry 2). 
Additionally, testing the yield of the reaction at different times 
revealed that conversion of 3a was >95% after 85 h (entry 10). 
This is of a great importance since MeOH has been considered 
one of the preferred green solvents.7 
 With these values in hand, we also explored the viability of 
the formation of intermediates 3b,c,f when using three other 
common anilines (2b,c,f), in order to prove if MeOH was also a 
useful solvent for other reagents (Scheme 2). 
 
 
Scheme 2. Test of different anilines 
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 The screening of different anilines revealed that the process 
was also applicable to other substrates with excellent yields for 
the synthesis of intermediate squaramide monoamines 3b,c,f 
(Scheme 2).  
 After confirming the compatibility of this method with 
different anilines, the viability of the one-pot process was tested 
by incorporating the third reaction component (amine 4) in the 
reaction medium after the formation of intermediate 3. A great 
number of anilines and amines were tested for the efficient 
formation of structures 5, which we are currently researching as 
promising organocatalysts for asymmetric catalysis (Table 2). 
Among them there were 15 new squaramide structures (entries 
1-16) and 11 structures that had previously been reported 
(entries 17-29). In our one-pot procedure, first we added amine 
2a-i in one portion into a solution of squarate 1a in MeOH, and 
after a reaction time of t1, we added the second amine 4a-l 
dissolved in MeOH. After a time of t2, the reaction was stopped 
and purified. Generally, the final products were purified by 
filtration, although in a few cases, these products were purified 
by column chromatography. 
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Table 2. Scope of the one-pot synthesis of squaramides 5.a  
 
 
Entry NH2R1 (2a-i)/ 
MeOH (mL) 
NH2R2 (4a-l)/ 
MeOH (mL) 
t1 (h) t2 (h) Product yield (%)b 
1 2a/0.25   4a/1.75 80 20 
 
75 
2 2b/0.5 4a/1.5 26 25 
 
82 
3 
4c 
2d/1 
2d/5 
4a/1 
4a/5 
2 
2.5 
2 
4 
N
H
O O
N
H HN
S
O
O
Me
5da
 
72 
80 
5 2e/0.5 4a/1.5 3 7 
 
85 
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6 2g/0.5 4a/1.5 20 3 
 
72 
7 2a/0.25 4b/1.75 82 10 
 
77 
8 2b/0.5 4b/1.5 48 14 
 
>95 
9c 2a/1.25 4c/5.75 82 3 
 
84 
10 2a/0.25 4d/1.75 82 14 
 
60 
11 2a/0.25 4e/1.75 49 3 
 
61 
12 2b/0.5 4e/1.5 35 5 
 
88 
13 2b/0.5 4f/4.5 30 3 
 
82 
14 2f/0.75 4g/1.25 66 3 
 
82 
15d 2h/0.75 4g/1.25 65 23 
 
68e 
16d 2h/0.75 4h/1.25 67 25 
 
50f 
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17g 2a/0.5 4g/3.5 77 2.5 
 
 
80h 
(43)10 (65)9 
18g 2c/1 4g/3 48 3 
 
 
77 
(58)10 (62)11 
19 
20g 
2a/0.25 
2a/0.5 
4j/1.75 
4j/3.5 
72 
76 
48 
45 
 
 
45i 
52i  
(49)12  
21 2c/0.5 4j/1.5 48 48 
 
 
48 or 64i 
(74)12  
22g 
 
2g/1 
 
 
4j/3 
 
 
26 
 
48 
N
NH
N
OMe
NHO
O
5gj
CF3
CF3  
 
56 or 74i  
(78)13 
23 2a/0.25 4k/1.75 77 25 
 
67i  
(49)12  
24 2c/0.5 4k/1.5 48 48 
N
NH
N
NHO
O
5ck
CF3  
68 or 78i  
(72)12  
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25 
26g 
2g/0.5 
 2g/1 
4l/1.5 
   4l/3 
22 
26 
48 
48 
 
 
43  
53 or 67i  
(61)4 
27 2g/0.5 4g/1.5 21 3 NH
O O
N
H N5gg
F3C
CF3  
 
43 
(34)14  
28 2i/1 4g/1 48 23 
 
53 
(30)15 
29 2a/0.25 4i/1.75 74 3 
 
 
60 
(29)10 (48)9  
a Experimental conditions: To a mixture of squarate 1a (0.2 mmol) in MeOH (0.25-1 mL), amine 2a-i (0.2 mmol) was added in one portion at room 
temperature. After the reaction time t1, amine 4a-l (0.2 mmol) was further added solved in MeOH (1-4.5 mL). After t2, adduct 5 was filtrated under vacuum, 
placed at -22 ºC for 30 minutes and the solid was washed with cold MeOH (1 mL). b Isolated yield. The results in parenthesis are the yields obtained by 
previous authors in the respective two-step syntheses. c Reaction performed for 1 mmol of reagents. d Reaction performed for 0.15 mmol of reagents. e Purified 
by column chromatography (SiO2, using Hex:EtOAc 6:4 to EtOAc:MeOH 9:1). f Purified by column chromatography (SiO2, using EtOAc to EtOAc:MeOH 
7:3). g Reaction performed for 0.4 mmol of reagents. h Purified by column chromatography (SiO2 treated with Et3N, using CH2Cl2 to CH2Cl2:MeOH 98:2). i 
Purified by column chromatography (SiO2, using Hex:EtOAc 6:4 to EtOAc:MeOH 7:3). 
 
 In every reaction, final squaramides 5 were produced in 
moderate to very good yields (from 43% to >95% yield). 
Unless otherwise indicated, the products were purified by a 
simple filtration of the final solid under vacuum conditions and 
washed with cold MeOH. We were encouraged to observe that 
it was possible to slightly increase the yield of the process by 
performing the reactions on a larger scale (with 0.4 or 1 mmol 
of reagents, entries 4, 20 and 26). When performing these 
reactions at a larger scale, the loss of material reduced the 
overall yield less than at a small scale (72% vs 80% in entries 3 
and 4, 45% vs 52% in entries 19 and 20, and 43% vs 53% in 
entries 25 and 26). This is also interesting from an industrial 
point of view because even better yields could be expected at 
an industrial scale. The concentration of each reaction has been 
studied and optimised individually, based on the different 
insolubilities of the reagents and the final products. However, 
despite each reaction having its own optimization process, only 
slight modifications in the amounts of MeOH used in the 
reactions were necessary (Table 1). In most of the comparisons, 
the new one-pot procedure gave better results than the previous 
two-step approaches, showing an increase in yield of up to 23% 
compared to the highest values previously reported (entry 28). 
However, squaramides 5cj (entry 21) and 5gj (entry 22) were 
obtained in slightly lower yields than those previously reported 
in the “stop-and-go” procedures. In our case, the slightly lower 
yield could be attributed to the small scale at which the 
reactions were performed, but better results could be expected 
when these processes are scaled-up as we have already 
demonstrated for some examples.  
 Interestingly, the commercially available squaramide 
organocatalyst 5cg was obtained with a better yield when 
compared to the previously reported syntheses of the same 
compound (see Scheme 3 and Table 2, entry 18).10,11 In the 
previous procedures, the authors used an excess of amine 4g 
(1.5 equiv.), the most expensive part of this squaramide 
structure, in the second reaction step. However, we performed 
the reaction using equimolar amounts of each reagent in order 
to reduce the waste and costs involved in the process. 
Moreover, we stopped the reaction 3 hours after adding second 
amine 4g, which is a notably shorter reaction time than those in 
previous procedures (24 h, Scheme 3). As mentioned above, the 
yield of this process may be increased if the reaction is scaled 
up. 
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Scheme 3. Syntheses of commercially available squaramide 5cg 
 
 After these promising results, we considered extending the 
applicability of our simple, cheap and straightforward 
methodology to the synthesis of biologically active compounds, 
in order to enlarge the scope of this method and to demonstrate 
the importance and applications of this pioneering one-pot 
procedure. 
 Recently, Moreno, Costa and co-workers have discovered 
an effective antiparasitic agent that acts as an anti-Chagasic 
drug (Scheme 4). Squaramide 10 has resulted to be a promising 
candidate in the preliminary in vivo studies on acute and 
chronic phases of Chagas disease and has shown low toxicity.16 
This disease is a tropical parasitic infection that mainly affects 
to the poorest rural areas of Latin America, and although there 
are treatments for this illness, more efforts in research as well 
as more efficient and less expensive drugs are required to 
combat Chagas disease.17 In this context, squaramide 10, as a 
low-cost drug, could represent an interesting alternative to the 
medicines that are currently being used for this disease, the 
later having severe side effects and not being effective for 
chronic patients. 
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Scheme 4. Syntheses of anti‐Chagasic squaramide 10 
 
  The results previously reported for the production of this 
interesting compound16 were improved when using our 
synthetic method. In the previous synthesis, the authors needed 
three sequential transformations with an overall yield for the 
last two steps of around 67.5%. In contrast, we started our 
synthesis from squarate 1a dissolved in MeOH (0.25 mL), and 
then added amine 7. In the same vessel, after 2.5 h we added 
BuNH2 (9) dissolved in MeOH (1.75 mL). After 12.5 h, the 
product was then purified by column chromatography, 
obtaining the final product 10 in a 78% yield. Therefore, the 
yield achieved using our one-pot procedure was higher than 
that of the previous three-step process. 
 This simple and inexpensive method might attract the 
interest of pharmaceutical companies for the production of this 
compound at a larger scale. This could help to overcome one of 
the drawbacks that this disease now presents: the high cost of 
the drugs used to fight it, which makes the treatment 
inaccessible for many people affected by this illness. 
 
 We also prepared two other active compounds, 14 and 18, 
as potent smooth muscle relaxants (Schemes 5 and 6). These 
two bladder-selective KATP-channel openers18 exhibit 
remarkable oral efficacy in a rat hypertrophied bladder model 
of urge urinary incontinency,19 a disease that affects between 10 
to 20 percent of the worldwide population and causes enormous 
health care expenses. The therapeutic drugs that are currently 
being used to treat this disease, such as tolterodine, a 
muscarinic antagonist, present some drawbacks that limit their 
use and special care must be taken when supplying these drugs. 
These side effects have made it necessary to search for new 
candidates with different mechanisms of action that show 
enhanced efficacy and work in a wide range of patients. In this 
sense, WAY-133537 (14) and WAY-151616 (18) have been 
revealed as promising drug candidates since they show bladder 
selectivity without causing severe cardiovascular side effects. 
 
 
 
 
 
Scheme 5. Syntheses of biologically active WAY‐133537 (14) 
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 The pioneering synthesis of compound 14 is described in 
Scheme 5 with an overall yield of 17.7% (scale of 5.88 
mmol).20 Squaramide derivative 14 has been successfully tested 
in urinary incontinence disorder, but it is also efficient in the 
treatment of other diseases related to smooth muscle 
contraction such as hypertension, asthma, premature labor, 
irritable bowel syndrome, congestive heart failure, angina and 
cerebral vascular disease.21 The one-pot method that we have 
developed was also successfully employed in the synthesis of 
this appealing drug and it was possible to synthesise it in a 33% 
yield (at a scale of 0.2 mmol). In this case, the initial amount of 
solvent was slightly modified due to the high insolubility of 
intermediate 12, starting from squarate 1a and amine 11 
dissolved in 1 mL of MeOH. After 73 h of reaction, we added 
amine 13 as a liquid without MeOH. Finally, after 2 days the 
precipitate was filtered under vacuum and the solid was washed 
with cold MeOH (1 mL), obtaining the final product 14 in a 
33% yield. 
 In addition, we also prepared WAY-151616 (18) using our 
new synthetic approach. Squaramide 18 is another potent 
potassium channel opener with specificity towards bladder 
tissue, which has also shown promising results as potential drug 
in the treatment of urge urinary incontinence and it is already 
being produced industrially (Scheme 6).21d,22 
 
 
Scheme 6. Syntheses of biologically active WAY‐151616 (18) 
 
 Biologically active squaramide 18 was prepared by Butera 
and co-workers following the procedure described in Scheme 6, 
with an overall yield of 79%.23 Employing our one-pot method, 
we reached a 72% yield in one single step. It is noteworthy that 
the authors performed this synthesis to obtain around 28 g of 
compound 18 while we were operating on a very small scale 
(0.4 mmol of product, 136 mg). Therefore, a higher yield 
should be expected when employing our methodology on a 
larger scale. When we performed the reaction at a smaller scale 
(0.2 mmol), the final product was rendered with a 62% yield, 
displaying the importance of scale and the possibility of 
improving our method by increasing the amount of product 
synthesised. 
 
Conclusions 
In summary, we have reported the first one-pot synthesis of 
squaramides with results from moderate to very good. This is a 
simpler procedure for obtaining appealing squaramide 
derivatives when compared to the previously developed “stop-
and-go” processes. This method is energy-saving, avoids time 
consuming purification steps and reduces costs, leading, in 
most cases, to better yields when compared to those obtained 
through the traditional sequential approach. 
 Furthermore, we have proved the utility of our process with 
the synthesis of three biologically active structures, improving 
upon the results of the previous stepwise syntheses. Moreover, 
we have been able to synthesise the commercially available 
squaramide 5cg, which is being employed extensively as an 
organocatalyst, using this one-pot method and obtaining higher 
yields than those of previous works. This simple and 
inexpensive method could attract the interest of pharmaceutical 
and chemical companies aiming to produce these compounds at 
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a large scale. We believe that our work could be a pivotal and 
crucial precedent in the field of squaramides due to the 
simplicity of the operational procedure reported here. 
 
 
 
Experimental 
General Experimental Methods 
When need it, purification of reaction products was carried out 
by flash chromatography using silica-gel (0.063-0.200 mm). 
Analytical thin layer chromatography was performed on 0.25 
mm silical gel 60-F plates. ESI ionization method and mass 
analyzer type MicroTof-Q were used for the ESI 
measurements. 1H NMR spectra were recorded at 400 and 300 
MHz; 13C APT-NMR spectra were recorded at 100 and 75 
MHz; DMSO-d6 and CDCl3 as the solvents. Chemical shifts 
were reported in the δ scale relative to residual CHCl3 (7.26 
ppm) and DMSO (2.50 ppm) for 1H NMR and to the central 
line of CHCl3 (77 ppm) and DMSO (39.43 ppm) for 13C APT-
NMR. 
All commercially available solvents and reagents were used as 
received. The 1H and 13C NMR spectra for compounds 5ag9 
5cg,10 5aj,12 5cj,12 5gj,13 5ak,12 5ck,12 5gl,4 5gg,14 5ig,15 5ai,9 
10,16 14,20 and 1823 are consistent with values previously 
reported in the literature. 
Representative procedure for the one-pot synthesis of 
squaramides 5 
To a mixture of 3,4-dimethoxy-3-cyclobutene-1,2-dione (1a) 
(0.2 mmol) in MeOH (0.25-1 mL), amine 2a-i was firstly added 
in one portion at room temperature. After the corresponding 
reaction time (t1) (see Table 1), amine 4a-l (1 equivalent) was 
then added dissolved in MeOH (1.75-1 mL). After the 
corresponding reaction time (t2) (see Table 1), the product was 
purified by filtration or by column chromatography. Yields are 
reported in Table 1 and pure compounds were obtained as 
stable solids. 
 
One-pot synthesis of antiparasitic agent 10 
To a mixture of 3,4-dimethoxy-3-cyclobutene-1,2-dione (1a) 
(0.2 mmol) in MeOH (0.25 mL), 0.2 mmol of N,N,N’-
trimethyl-1,3-propanediamine (7) was firstly added at room 
temperature in one portion. After 2.5 h, n-butylamine (9) (0.2 
mmol) was solved in MeOH (1.75 mL) and added to the 
reaction mixture in one portion. After 12.5 h, the solvent was 
evaporated in vacuum and the product was purified by column 
chromatography (SiO2, EtOAc:MeOH 1:1 to 
EtOAc:MeOH:Et3N 5:5:0.1). Final anti-Chagasic drug 10 was 
obtained as a white solid in 78% yield. 
 
One-pot synthesis of WAY-133537 (14) 
To a mixture of 3,4-dimethoxy-3-cyclobutene-1,2-dione (1a) (0.2 
mmol) in MeOH (1 mL), 0.2 mmol of 4-amino-3-ethylbenzonitrile 
(11) was firstly added at room temperature in one portion. After 73 
h, 0.2 mmol of (R)-3,3-dimethyl-2-butylamine (13) was added to the 
reaction mixture in one portion. After 48 h, the test tube was placed 
in a freezer (-22 ºC) for 30 minutes to facilitate the overall 
precipitation of final drug 14. The product was filtered under 
vacuum and washed with cold MeOH (1 mL). Final bladder-
selective agonist KATP channel 14 was obtained as a green solid in 
33% yield. 
 
One-pot synthesis of WAY-151616 (18) 
To a mixture of 3,4-dimethoxy-3-cyclobutene-1,2-dione (1a) 
(0.4 mmol) in MeOH (0.5 mL), 0.4 mmol of 1,1-
dimethylpropylamine (15) were firstly added at room 
temperature in one portion. After 20 h, 0.4 mmol of 2,4-
dichloro-6-methylbenzylamine (17) were solved in MeOH (3.5 
mL) and added to the reaction mixture in one portion. After 72 
h, the solvent was evaporated under vacuum and the product 
was purified by column chromatography (SiO2, hexane/EtOAc 
6:4 to 0:1 and EtOAc/MeOH 9:1. Final bladder-selective 
agonist KATP channel 18 was obtained as a white solid in 72% 
yield. 
 
N-((1R,2R)-2-(2-(3,5-Bis(trifluoromethyl)phenylamino)-3,4-
dioxocyclobut-1-enylamino)cyclohexyl)-4-
methylbenzenesulfonamide (5aa)  
Following the general procedure, compound 5aa was obtained after 
100 h of reaction at room temperature as a white solid in 75% yield. 
[α]D25 = +34 (c 0.55, DMSO). 1H NMR (400 MHz, DMSO-d6) δ 
10.02 (br s, 1H), 8.06 (s, 2H), 7.74 (br d, J = 8.5 Hz, 1H), 7.69 (s, 
1H), 7.63 (br d, J = 8.9 Hz, 1H), 7.59 (d, J = 8.2 Hz, 2H), 7.21 (d, J 
= 8.0 Hz, 2H), 3.62-3.52 (m, 1H), 3.18-3.05 (m, 1H), 2.13 (s, 3H), 
1.92-1.89 (m, 1H), 1.72-1.37 (m, 4H), 1.35-1.10 (m, 3H). 13C APT-
NMR (100 MHz, DMSO-d6) δ 183.8 (1C), 179.8 (1C), 169.5 (1C), 
162.0 (1C), 141.7 (1C), 141.1 (1C), 139.3 (1C), 131.4 (q, J = 34.2 
Hz, 2C), 130.9 (2C), 125.9 (2C), 123.1 (q, J = 271.7 Hz, 2C), 117.6 
(2C), 114 (1C), 57.3 (1C), 56.8 (1C), 32.7 (1C), 32.6 (1C), 24.0 
(1C), 24.0 (1C), 20.5 (1C). IR (KBr film) (cm–1) ν 3284, 3177, 2924, 
2854, 1793, 1659, 1582, 1559, 1457, 1379, 1277, 1191, 1163, 1151, 
1129, 1093, 880, 754, 666. HRMS (ESI+) calcd C25H24F6N3O4S 
576.1392; found 576.1360 [M+H]. 
 
N-((1R,2R)-2-(2-(3,5-Difluorophenylamino)-3,4-
dioxocyclobut-1-enylamino)cyclohexyl)-4- 
methylbenzenesulfonamide (5ba)  
Following the general procedure, compound 5ba was obtained 
after 51 h of reaction at room temperature as a white solid in 
82% yield. [α]D25 = +42 (c 0.49, DMSO). 1H NMR (400 MHz, 
DMSO-d6) δ 9.69 (br s, 1H), 7.70 (d, J = 8.5 Hz, 1H), 7.67 (d, J 
= 8.8 Hz, 1H), 7.59 (d, J = 7.9 Hz, 2H), 7.23-7.18 (m, 4H), 6.86 
(t, J = 9.2 Hz, 1H), 3.60-3.53 (m, 1H), 3.16-3.09 (m, 1H), 2.17 
(s, 3H), 1.92-1.89 (m, 1H), 1.64-1.11 (m, 7H). 13C APT-NMR 
(100 MHz, DMSO-d6) δ 183.6 (1C), 179.6 (1C), 169.2 (1C), 
163.0 (d, J = 242.7 Hz, 1C), 162.9 (d, J = 243.9 Hz, 1C), 162.4 
(1C), 141.9 (1C), 141.8 (t, J = 13.8 Hz, 1C), 139.3 (1C), 129.2 
(2C), 125.9 (2C), 100.9 (d, J = 29.6 Hz, 2C), 97.1 (t, J = 26.6 
Hz, 1C), 57.2 (1C), 56.9 (1C), 32.8 (1C), 32.6 (1C), 24.0 (1C), 
24.0 (1C), 20.6 (1C). IR (KBr film) (cm–1) ν 3369, 3289, 3189, 
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3044, 2924, 2854, 1797, 1664, 1616, 1575, 1536, 1461, 1377, 
1319, 1205, 1158, 1118, 1089, 994, 854, 749, 670, 571. MS 
(ESI+) 476.2 [M+H]. 
 
N-((1R,2R)-2-(2-(4-tert-Butylphenylamino)-3,4-dioxocyclobut-1-
enylamino)cyclohexyl)-4-methylbenzenesulfonamide (5da) 
Following the general procedure, compound 5da was obtained 
after 6.5 h of reaction at room temperature as a white solid in 
80% yield. [α]D24 = +48 (c 0.52, DMSO). 1H NMR (400 MHz, 
DMSO-d6) δ 9.40 (br s, 1H), 7.65 (br d, J = 8.1 Hz, 1H), 7.59 
(d, J = 8.2 Hz, 2H), 7.51 (br d, J = 7.1 Hz, 1H), 7.43-7.35 (m, 
4H), 7.21 (d, J = 8.1 Hz, 2H), 3.60-3.43 (m, 1H), 3.12-3.07 (m, 
1H), 2.13 (s, 3H), 1.94-1.87 (m, 1H), 1.69-1.11 (m, 7H), 1.28 
(s, 9H). 13C APT-NMR (100 MHz, DMSO-d6) δ 183.0 (1C), 
179.8 (1C), 168.6 (1C), 163.5 (1C), 144.9 (1C), 142.0 (1C), 
139.2 (1C), 136.5 (1C), 129.2 (2C), 125.9 (4C), 117.5 (2C), 
57.0 (1C), 56.9 (1C), 33.9 (1C), 32.9 (1C), 32.7 (1C), 31.1 
(3C), 24.1 (1C), 24.0 (1C), 20.6 (1C). IR (KBr film) (cm–1) ν 
3343, 3195, 2924, 2854, 1795, 1660, 1604, 1568, 1535, 1460, 
1375, 1322, 1268, 1162, 1143, 1094, 829, 723, 667. HRMS 
(ESI+) calcd C27H34N3O4S 469.2270; found 469.2233 [M+H]. 
 
N-((1R,2R)-2-(2-(4-Methoxyphenylamino)-3,4-
dioxocyclobut-1-enylamino)cyclohexyl)-4-
methylbenzenesulfonamide (5ea)  
Following the general procedure, compound 5ea was obtained 
after 10 h of reaction at room temperature as a white solid in 
85% yield. [α]D24 = +40 (c 0.58, DMSO). 1H NMR (400 MHz, 
DMSO-d6) δ 9.35 (br s, 1H), 7.64 (br d, J = 8.4 Hz, 1H), 7.59 
(d, J = 8.2 Hz, 2H), 7.42 (br d, J = 7.1 Hz, 1H), 7.37 (d, J = 8.7 
Hz, 2H), 7.22 (d, J = 8.0 Hz, 2H), 6.95 (d, J = 9.0 Hz, 2H), 3.74 
(s, 3H), 3.59-3.50 (m, 1H), 3.16-3.06 (m, 1H), 2.16 (s, 3H), 
1.91-1.88 (m, 1H), 1.67-1.17 (m, 7H). 13C APT-NMR (100 
MHz, DMSO-d6) δ 182.6 (1C), 179.9 (1C), 168.3 (1C), 163.4 
(1C), 155.0 (1C), 142.0 (1C), 139.2 (1C), 132.2 (1C), 129.2 
(2C), 125.9 (2C), 119.2 (2C), 114.5 (2C), 56.9 (1C), 56.9 (1C), 
55.2 (1C), 32.9 (1C), 32.8 (1C), 24.1 (1C), 24.0 (1C), 20.7 
(1C). IR (KBr film) (cm–1) ν 3348, 3266, 2922, 2853, 1790, 
1646, 1613, 1564, 1538, 1515, 1477, 1368, 1323, 1251, 1160, 
1094, 1077, 829, 810, 665. HRMS (ESI+) calcd C24H28N3O5S 
470.1750; found 470.1729 [M+H]. 
 
N-((1R,2R)-2-(2-(3,5-Bis(trifluoromethyl)benzylamino)-3,4-
dioxocyclobut-1-enylamino)cyclohexyl)-4-
methylbenzenesulfonamide (5ga)  
Following the general procedure, compound 5ga was obtained 
after 23 h of reaction at room temperature as a white solid in 
72% yield (85 mg). [α]D24 = +33 (c 0.49, DMSO). 1H NMR 
(400 MHz, DMSO-d6) δ 8.09 (s, 2H), 8.05 (s, 1H), 7.80 (br s, 
1H), 7.61 (d, J = 8.2 Hz, 2H), 7.57 (br s, 1H), 7.38 (br s, 1H), 
7.27 (d, J = 8.1 Hz, 2H), 4.90 (br s, 2H), 3.60-3.45 (m, 1H), 
3.04-2.94 (m, 1H), 2.33 (s, 3H), 1.86-1.80 (m, 1H), 1.60-1.01 
(m, 7H). 13C APT-NMR (100 MHz, DMSO-d6) δ 182.1 (1C), 
168.0 (1C), 142.5 (1C), 141.1 (2C), 139.3 (2C), 130.4 (q, J = 
32.5 Hz, 2C), 129.3 (2C), 128.4 (2C), 126.0 (2C), 123.2 (q, J = 
271.2 Hz, 2C), 121.1 (1C), 56.9 (1C), 56.7 (1C), 45.6 (1C), 
32.8 (1C), 32.1 (1C), 24.0 (2C), 20.8 (1C). IR (KBr film) (cm–
1) ν 3373, 3166, 2924, 2854, 1798, 1650, 1569, 1496, 1456, 
1377, 1321, 1268, 1237, 1203, 1186, 1171, 1095, 894, 729, 
706, 682, 568. MS (ESI+) 590.2 [M+H]. 
 
(S)-3-(3,5-bis(Trifluoromethyl)phenylamino)-4-(2-hydroxy-
1,2,2-triphenylethylamino)cyclobut-3-ene-1,2-dione (5ab) 
Following the general procedure, compound 5ab was obtained 
after 92 h of reaction at room temperature as a white solid in 
77% yield. [α]D25 = -97 (c 0.40, DMSO). 1H NMR (400 MHz, 
DMSO-d6) δ 10.40 (br s, 1H), 8.74 (br d, J = 9.6 Hz, 1H), 8.00 
(s, 2H), 7.67 (d, J = 7.5 Hz, 2H), 7.63 (s, 1H), 7.41-7.05 (m, 
13H), 6.71 (br s, 1H), 6.22 (br d, J = 9.7 Hz, 1H). 13C APT-
NMR (100 MHz, DMSO-d6) δ 184.6 (1C), 179.9 (1C), 168.3 
(1C), 162.5 (1C), 145.5 (1C), 144.1 (1C), 140.8 (1C), 138.9 
(1C), 131.2 (q, J = 31.6 Hz, 2C), 128.8 (2C), 128.0 (2C), 127.5 
(1C) 127.4 (2C), 127.0 (1C), 126.7 (1C), 126.5 (1C), 126.3 
(1C), 126.1 (2C), 126.0 (2C), 123.0 (q, J = 271.0 Hz, 2C), 
118.0 (2C), 114.6 (1C), 80.4 (1C), 63.3 (1C). IR (KBr film) 
(cm–1) ν 3506, 3220, 3135, 2923, 2854, 1804, 1660, 1604, 
1575, 1546, 1506, 1469, 1380, 1280, 1184, 1128, 1062, 889, 
752, 699. HRMS (ESI+) calcd C32H23F6N2O3 597.1613; found 
597.1599 [M+H]. 
 
(S)-3-(3,5-Difluorophenylamino)-4-(2-hydroxy-1,2,2-
triphenylethylamino)cyclobut-3-ene-1,2-dione (5bb) 
Following the general procedure, compound 5bb was obtained 
after 62 h of reaction at room temperature as a white solid in 
>95% yield. [α]D27 = -197 (c 0.65, DMSO). 1H NMR (400 
MHz, DMSO-d6) δ 10.12 (br s, 1H), 8.73 (br d, J = 9.7 Hz, 1H), 
7.6 (d, J = 7.5 Hz, 2H), 7.35 (t, J = 7.6 Hz, 2H), 7.25-7.05 (m, 
13H), 6.85-6.79 (m, 1H), 6.69 (br s, 1H), 6.23 (br d, J = 9.8 Hz, 
1H). 13C APT-NMR (100 MHz, DMSO-d6) δ 184.5 (1C), 179.7 
(1C), 168.1 (1C), 162.9 (d, J = 242.5 Hz, 1C), 162.8 (1C), 
162.7 (d, J = 232.5 Hz, 1C), 145.6 (1C), 144.1 (1C), 141.5 (t, J 
= 13.7 Hz, 1C), 139.0 (1C), 128.9 (2C), 128.0 (2C), 127.4 (4C) 
127.0 (1C), 126.7 (1C), 126.5 (1C), 126.2 (2C), 126.1 (2C), 
101.2 (d, J = 29.5 Hz, 2C), 97.4 (t, J = 26.5 Hz, 1C) 80.4 (1C), 
63.3 (1C). IR (KBr film) (cm–1) ν 3483, 3446, 3227, 3122, 
2924, 2853, 1800, 1656, 1608, 1565, 1493, 1465, 1377, 1188, 
1166, 1119, 1065, 1004, 891, 761, 750, 728, 697. MS (ESI) 
497.2 [M+H]. 
 
(R)-3-(3,5-Bis(trifluoromethyl)phenylamino)-4-(1-
phenylethylamino)cyclobut-3-ene-1,2-dione (5ac)  
Following the general procedure, compound 5ac was obtained 
after 85 h of reaction at room temperature as a white solid in 
84% yield. [α]D27 = -6 (c 0.87, DMSO). 1H NMR (400 MHz, 
DMSO-d6) δ 10.06 (br s, 1H), 8.15 (br s, 1H), 8.01 (s, 2H), 7.67 
(s, 1H), 7.44-7.30 (m, 5H), 5.36-5.27 (m, 1H), 1.61 (d, J = 6.9 
Hz, 3H). 13C APT-NMR (100 MHz, DMSO-d6) δ 184.3 (1C), 
180.5 (1C), 168.8 (1C), 162.5 (1C), 142.7 (1C), 140.9 (1C), 
131.2 (q, J = 34.0 Hz, 2C), 128.6 (2C), 127.5 (1C), 126.0 (2C), 
123.0 (q, J = 271.2 Hz, 2C), 118.0 (2C), 114.7 (1C), 53.3 (1C), 
22.7 (1C). IR (KBr film) (cm–1) ν 3135, 2924, 1797, 1661, 
  | 13 
1570, 1559, 1491, 1456, 1377, 1275, 1188, 1170, 1129, 944, 
883, 750, 697, 683, 667. MS (ESI+) 429.1 [M+H]. 
 
(R)-3-(3,5-Bis(trifluoromethyl)phenylamino)-4-(1-hydroxy-
3-phenylpropan-2-ylamino)cyclobut-3-ene-1,2-dione (5ad) 
Following the general procedure, compound 5ad was obtained 
after 96 h of reaction at room temperature as a white solid in 
60% yield. [α]D24 = +125 (c 0.54, DMSO). 1H NMR (400 MHz, 
DMSO-d6) δ 9.78 (br s, 1H), 7.59 (s, 2H), 7.47 (br d, J = 9.0 
Hz, 1H), 7.19 (s, 1H), 6.85-6.73 (m, 5H), 4.78 (br s, 1H), 3.90-
3.80 (m, 1H), 3.15-3.06 (m, 2H), 2.51 (dd, J = 6.6, 13.6 Hz, 
1H), 2.38 (dd, J = 7.9, 13.4 Hz, 1H). 13C APT-NMR (100 MHz, 
DMSO-d6) δ 184.2 (1C), 180.1 (1C), 169.5 (1C), 162.0 (1C), 
141.1 (1C), 137.8 (1C), 131.3 (q, J = 33.6 Hz, 2C), 129.2 (2C), 
128.2 (2C), 126.2 (1C), 123.1 (q, J = 270.9 Hz, 2C), 117.7 
(2C), 114.5 (1C), 62.2 (1C), 57.4 (1C), 38.0 (1C). IR (KBr 
film) (cm–1) ν 3280, 3044, 2923, 2853, 1790, 1690, 1605, 1576, 
1553, 1499, 1477, 1455, 1388, 1280, 1181, 1171, 1131, 1030, 
899, 882, 701. HRMS (ESI+) calcd C21H17F6N2O3 459.1144; 
found 459.1130 [M+H]. 
 
3-(3,5-Bis(trifluoromethyl)phenylamino)-4-((1S,2R)-2-
hydroxy-2,3-dihydro-1H-inden-1-ylamino)cyclobut-3-ene-
1,2-dione (5ae)  
Following the general procedure, compound 5ae was obtained 
after 52 h of reaction at room temperature as a white solid in 
61% yield. [α]D27 = +81 (c 0.48, DMSO). 1H NMR (400 MHz, 
DMSO-d6) δ 10.46 (br s, 1H), 8.16 (br d, J = 9.0 Hz, 1H), 8.10 
(s, 2H), 7.65 (s, 1H), 7.32-7.22 (m, 4H), 5.62 (br s, 1H), 5.53 
(dd, J = 5.0, 8.7 Hz, 1H), 4.65-4.55 (m, 1H), 3.16 (dd, J = 4.8, 
16.4 Hz, 1H), 2.89 (d, J = 16.2 Hz, 1H). 13C APT-NMR (100 
MHz, DMSO-d6) δ 184.6 (1C), 180.4 (1C), 169.5 (1C), 162.6 
(1C), 141.2 (1C), 141.2 (1C), 140.5 (1C), 131.3 (q, J = 32.7 Hz, 
2C), 128.0 (2C), 126.6 (1C), 125.1 (1C), 124.2 (1C), 123.1 (q, J 
= 271.1 Hz, 2C), 117.8 (2C), 114.5 (1C), 72.2 (1C), 62.2 (1C). 
IR (KBr film) (cm–1) ν 3278, 2958, 2927, 2854, 1792, 1691, 
1597, 1552, 1482, 1465, 1442, 1383, 1334, 1300, 1190, 1128, 
1043, 933, 897, 742, 685. MS (ESI+) 457.1 [M+H]. 
 
3-(3,5-Difluorophenylamino)-4-((1S,2R)-2-hydroxy-2,3-
dihydro-1H-inden-1-ylamino)cyclobut-3-ene-1,2-dione (5be) 
Following the general procedure, compound 5be was obtained 
after 40 h of reaction at room temperature as a white solid in 
88% yield. [α]D27 = +48 (c 0.47, DMSO). 1H NMR (400 MHz, 
DMSO-d6) δ 10.16 (br s, 1H), 8.17 (br d, J = 9.4 Hz, 1H), 7.32-
7.23 (m, 6H), 6.85 (t, J = 9.5 Hz, 1H), 5.58 (br s, 1H), 5.52 (dd, 
J = 5.0, 9.0 Hz, 1H), 4.60-4.56 (m, 1H), 3.14 (dd, J = 4.0, 15.7 
Hz, 1H), 2.87 (d, J = 16.3 Hz, 1H). 13C APT-NMR (100 MHz, 
DMSO-d6) δ 184.4 (1C), 180.2 (1C), 169.3 (1C), 163.0 (d, J = 
238.2 Hz, 1C), 162.8 (1C), 162.9 (d, J = 242.5 Hz, 1C), 141.9 
(t, J = 13.7 Hz, 1C), 141.1 (1C), 140.5 (1C), 128.0 (1C), 126.6 
(1C), 125.1 (1C), 124.2 (1C), 101.0 (d, J = 29.4 Hz, 2C), 97.2 
(d, J = 26.1 Hz, 1C), 72.3 (1C), 61.2 (1C), 39.4 (1C). IR (KBr 
film) (cm–1) ν 3460, 3261, 2922, 2852, 1794, 1662, 1613, 1576, 
1559, 1541, 1446, 1416, 1377, 1208, 1149, 1119, 1090, 1022, 
995, 977, 854, 752, 727, 686, 646. MS (ESI+) 357.1 [M+H]. 
 
(S)-3-(3,5-Difluorophenylamino)-4-(1-(naphthalen-1-
yl)ethylamino)cyclobut-3-ene-1,2-dione (5bf)  
Following the general procedure, compound 5bf was obtained 
after 33 h of reaction at room temperature as a white solid in 
82% yield. [α]D27 = +184 (c 0.44, DMSO). 1H NMR (400 MHz, 
DMSO-d6) δ 9.80 (br s, 1H), 8.28 (br d, J = 6.9 Hz, 1H), 8.14 
(d, J = 8.4 Hz, 1H), 7.99 (d, J = 7.8 Hz, 1H), 7.93 (d, J = 8.0 
Hz, 1H), 7.67-7.55 (m, 4H), 7.16 (br d, J = 7.6 Hz, 2H), 6.84 (t, 
J = 9.3 Hz, 1H), 6.17-6.08 (m, 1H), 1.75 (d, J = 6.7 Hz, 3H). 
13C APT-NMR (100 MHz, DMSO-d6) δ 184.1 (1C), 180.1 
(1C), 168.4 (1C), 162.9 (d, J = 242.5 Hz, 1C), 162.8 (1C), 
162.8 (d, J = 242.5 Hz, 1C), 141.6 (t, J = 13.7 Hz, 1C), 138.1 
(1C), 133.4 (1C), 129.9 (1C), 128.7 (1C), 128.2 (1C), 126.7 
(1C), 125.9 (1C), 125.4 (1C), 122.7 (1C), 122.6 (1C), 101.1 (d, 
J = 29.4 Hz, 2C), 97.4 (t, J = 26.2 Hz, 1C), 49.4 (1C), 22.7 
(1C). IR (KBr film) (cm–1) ν 3165, 3080, 3017, 2924, 2854, 
1793, 1664, 1631, 1609, 1460, 1375, 1307, 1153, 1116, 993, 
854, 835, 804, 782, 754. MS (ESI+) 379.2 [M+H]. 
 
3-((1R,2R)-2-(Piperidin-1-yl)cyclohexylamino)-4-(3,4,5-
trifluorophenylamino)cyclobut-3-ene-1,2-dione (5fg) 
Following the general procedure, compound 5fg was obtained 
after 69 h of reaction at room temperature as a white solid in 
82% yield. [α]D25 = -54 (c 0.40, DMSO). 1H NMR (400 MHz, 
DMSO-d6) δ 9.92 (br s, 1H), 7.52 (br s, 1H), 7.33 (d, J = 9.7 
Hz, 1H), 7.31 (d, J = 9.5 Hz, 1H), 4.02-3.85 (m, 1H), 2.76-2.56 
(m, 2H), 2.39-2.17 (m, 3H), 2.10-1.97 (m, 1H), 1.91-1.80 (m, 
1H), 1.79-1.60 (m, 2H), 1.51-1.00 (m, 10H). 13C APT-NMR 
(100 MHz, DMSO-d6) δ 184.5 (1C), 180.1 (1C), 169.6 (1C), 
161.7 (2C), 150.6 (dd, J = 10.0, 245.8 Hz, 1C), 150.5 (dd, J = 
10.0, 244.7 Hz, 1C), 134.3 (dt, J = 15.6, 243.0 Hz, 1C), 102.5 
(d, J = 23.7 Hz, 2C), 68.3 (1C), 54.3 (1C), 49.2 (1C), 33.6 (1C), 
26.2 (1C), 24.6 (2C), 24.4 (1C), 24.3 (1C), 23.2 (2C). IR (KBr 
film) (cm–1) ν 3194, 3084, 2924, 2853, 1796, 1657, 1631, 1575, 
1480, 1450, 1377, 1241, 1154, 1098, 1044, 980, 856, 799, 744, 
462. MS (ESI+) 408.2 [M+H]. 
 
3-((R)-2’-Hydroxy-1,1’-binaphthyl-2-ylamino)-4-((1R,2R)-2-
(piperidin-1-yl)cyclohexylamino)cyclobut-3-ene-1,2-dione 
(5hg)  
Following the general procedure, compound 5hg was obtained 
after 88 h of reaction at room temperature as a yellow solid in 
68% yield. [α]D24 = +85 (c 0.44, CHCl3). 1H NMR (300 MHz, 
CDCl3) δ 8.01 (d, J = 8.8 Hz, 1H), 7.92-7.79 (m, 3H), 7.62 (br 
d, J = 6.7 Hz, 1H), 7.40 (dt, J = 1.1, 8.0 Hz, 1H), 7.34-7.11 (m, 
5H), 6.96 (d, J = 8.3 Hz, 1H), 6.00 (br s, 2H), 3.85 (br s, 1H), 
2.77-2.10 (m, 6H), 1.91-1.51 (m, 3H), 1.49-0.99 (m, 11H). 13C 
APT-NMR (75 MHz, CDCl3) δ 184.1 (1C), 182.1 (1C), 168.4 
(1C), 163.8 (1C), 152.7 (1C), 134.5 (1C), 133.5 (1C), 133.4 
(1C), 131.53 (1C), 130.7 (1C), 130.1 (1C), 129.0 (2C), 128.2 
(2C), 127.4 (1C), 127.1 (1C), 125.7 (1C), 125.5 (1C), 124.1 
(1C), 123.5 (1C), 120.7 (1C), 118.8 (1C), 113.2 (1C), 67.9 
(1C), 54.2 (1C), 49.5 (2C), 34.8 (1C), 25.2 (1C), 24.9 (1C), 
24.2 (2C), 23.8 (1C), 23.2 (1C). IR (KBr film) (cm–1) ν 3251, 
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2924, 2854, 1792, 1683, 1595, 1505, 1463, 1377, 1338, 1261, 
1095, 1021, 801. MS (ESI+) 546.3 [M+H]. 
 
3-((R)-2’-Hydroxy-1,1’-binaphthyl-2-ylamino)-4-((1R,2R)-2-
(pyrrolidin-1-yl)cyclohexylamino)cyclobut-3-ene-1,2-dione 
(5hh) 
Following the general procedure, compound 5hh was obtained 
after 92 h of reaction at room temperature as a yellow solid in 
50% yield. [α]D24 = +227 (c 0.48, CHCl3). 1H NMR (400 MHz, 
CDCl3) 7.96 (d, J = 8.8 Hz, 1H), 7.89 (d, J = 8.1 Hz, 1H), 7.81 
(app. dd, J = 6.7, 7.5 Hz, 2H), 7.70-7.53 (m, 1H), 7.40 (t, J = 
7.4 Hz, 1H), 7.33-7.09 (m, 5H), 6.94 (d, J = 8.4 Hz, 1H), 6.32 
(br s, 2H), 3.72 (br s, 1H), 2.75-2.45 (m, 4H), 2.12-1.87 (m, 
1H), 1.80-1.40 (m, 4H), 1.39-0.73 (m, 9H). 13C APT-NMR 
(100 MHz, CDCl3) δ 183.7 (1C), 181.9 (1C), 168.5 (1C), 164.8 
(1C), 153.1 (1C), 134.5 (1C), 133.6 (1C), 133.3 (1C), 131.5 
(1C), 130.4 (1C), 129.5 (1C), 128.8 (2C), 128.2 (1C), 128.1 
(1C), 127.1 (1C), 126.9 (1C), 125.9 (1C), 125.5 (1C), 124.2 
(1C), 123.3 (1C), 121.7 (1C), 119.2 (1C), 114.1 (1C), 63.1 
(1C), 55.8 (1C), 48.0 (2C), 34.3 (1C), 29.7 (1C), 24.2 (1C), 
24.0 (1C), 23.5 (2C). IR (KBr film) (cm–1) ν 3240, 2924, 2854, 
1792, 1683, 1596, 1505, 1462, 1428, 1377, 1336, 1271, 815, 
748. MS (ESI+) 532.3 [M+H]. 
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